KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) EBT Margin (2017 - 2025)

Historic EBT Margin for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to 4851.71%.

  • Co-Diagnostics' EBT Margin fell 33428000.0% to 4851.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 6562.78%, marking a year-over-year decrease of 60521300.0%. This contributed to the annual value of 959.9% for FY2024, which is 4004400.0% down from last year.
  • As of Q3 2025, Co-Diagnostics' EBT Margin stood at 4851.71%, which was down 33428000.0% from 4737.46% recorded in Q2 2025.
  • Co-Diagnostics' EBT Margin's 5-year high stood at 57.71% during Q1 2022, with a 5-year trough of 14959.66% in Q1 2025.
  • Its 5-year average for EBT Margin is 2368.7%, with a median of 329.49% in 2023.
  • As far as peak fluctuations go, Co-Diagnostics' EBT Margin surged by 53551900bps in 2024, and later crashed by -129741500bps in 2025.
  • Quarter analysis of 5 years shows Co-Diagnostics' EBT Margin stood at 50.21% in 2021, then crashed by -3659bps to 1786.99% in 2022, then surged by 83bps to 304.98% in 2023, then plummeted by -2324bps to 7392.85% in 2024, then skyrocketed by 34bps to 4851.71% in 2025.
  • Its EBT Margin stands at 4851.71% for Q3 2025, versus 4737.46% for Q2 2025 and 14959.66% for Q1 2025.